ArticleJACC. Asia2026
Redo TAVR With Fluoroscopic-Free Surgical Resection of Prosthetic Valve Leaflets Under Direct Vision (SURPLUS) Technique.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a fluoroscopic-free approach to the Surgical Resection of Prosthetic Valve Leaflets Under Direct Vision (SURPLUS) technique. With expanding transcatheter aortic valve replacement (TAVR) volumes and broader indications, a failed transcatheter prosthesis is typically managed by redo TAVR. However, when bilateral coronary obstruction risk is prohibitively high and transcatheter leaflet modification techniques such as Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction or Undermining Iatrogenic Coronary Obstruction With Radiofrequency Needle, or coronary stenting, are not feasible, transcatheter aortic valve explantation remains an alternative, yet it is technically demanding and carries significant risk according to real-world data. SURPLUS was previously described as a hybrid option wherein the failed leaflets are excised while the original stent is left in situ, followed by surgical valve-in-valve deployment. Here, we describe a completely fluoroscopic-free execution of SURPLUS in an older patient with high bilateral coronary obstruction risk, detailing the method to determine implantation depth and achieve commissural alignment without fluoroscopic imaging. The procedure resulted in no coronary obstruction and demonstrated good immediate and 1-year outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.